APOA1 and atherosclerosis: Infusing reconstituted HDL (rHDL) or increasing HDL levels with overexpression of apolipoprotein A-I (ApoA-I), the major HDL apolipoprotein, reduced plaque size by altering the histological composition of experimental lesions in animal models of atherosclerosis and restenosis [7–12].